IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, March 2026
Impact Factor: 8.2

Shaping the Future of Medicine: Advances and Outlook in RNAi-Based Therapies

Prof. Pallavi T. Jadhav[1], Dr. Abhishek Kumar Sen[2], Mr. Akshay Babanrao Deogude[3]
[1]Assistant Professor, [2]Principal, [3]Studant
Pratibhatai Pawar College of Pharmacy Shrirampur, Ahilyanagar, Maharashtra, India

Abstract: *A novel method of gene silencing with substantial therapeutic potential is RNA interference (RNAi). Through the use of short RNA molecules like siRNAs and miRNAs, RNA interference (RNAi) makes it possible to specifically downregulate genes linked to disease, opening up new treatment options for complicated diseases, cancer, viral infections, and genetic abnormalities. Significant advancements in clinical translation have been made in recent years with the regulatory approval of a number of RNAi-based treatments. Despite these advancements, there are still significant obstacles to overcome, especially in the areas of immune response, stability, off-target effects, and targeted delivery. Research is still being done to extend therapeutic targets, improve safety profiles, and improve delivery platforms such lipid nanoparticles and conjugates. In addition to discussing new technologies and ways to get over current restrictions, this study looks at the clinical environment of RNAi treatments today and considers how flexible RNAi may become in precision medicine in the future. In almost every human cell, the RNA interference (RNA) pathway controls the stability and translation of mRNA. Although small double-stranded RNA molecules are effective in causing RNAi silence of particular genes, there have been many issues with their effectiveness and safety when used therapeutically. But a new era for the industry began in August 2018 when the US Food and Drug*
The first RNAi-based medication, ONPATTRO, has been approved by the administration. In this review, we go over the major developments in RNAi drug design and development that led to this historic accomplishment, the current status of the clinical pipeline, and potential future developments, such as novel RNAi pathway agents that employ mechanisms other than posttranslational RNAi silencing.

Keywords: RNA interference (RNAi),Gene silencing, Patisiran, small interference (siRNA)

I. INTRODUCTION

One of the natural biological mechanisms for controlling gene expression is RNA interference (RNA i). RNA interference (RNA i) has emerged as a viable method for gene silencing in biomedical research and treatment since its discovery. By facilitating the targeted breakdown of messenger RNA (mRNA), the process stops certain genes from translating. Therapeutic uses for this specificity have garnered a lot of interest, especially in the treatment of cancer, viral, and genetic disorders.

Overview of RNA i Mechanism:

Double-stranded RNA (ds RNA), which starts RNA interference (RNA i), is broken down into small interfering RNAs (si RNAs) of around 21–23 nucleotides by the enzyme Dicer. These siRNAs are part of the RNA-induced silencing complex (RISC), which is guided to complementary mRNA targets by the guide strand. After that, the RISC cleaves the mRNA, causing it to degrade and blocking the translation of proteins. (1). both short hairpin RNAs (siRNAs) and microRNAs (mi RNAs), which have different routes and regulatory functions,can mediate RNA interference in addition to siRNAs. (2).The Present Situation and Prospects of RNAi-Based Medicines Since regulatory bodies have approved a number of RNAi medications, RNAi-based therapies have made great progress. Patisiran, for instance, was the first siRNA therapy authorized by the FDA to treat hereditary transthyretin-mediated amyloidosis. (3). Givosiran

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, March 2026
Impact Factor: 8.2

and Lumasiran are two other noteworthy medications that treat acute hepatic porphyria and primary hyperoxaluria type 1, respectively. (4). These developments have been made possible by better delivery methods that improve the stability, targeting, and cellular uptake of RNAi molecules, such as lipid nanoparticles and GalNAc conjugates. RNAi therapies continue to encounter obstacles such immunogenicity, off-target effects, and effective tissue-specific delivery despite their achievements. Currently, research is concentrated on developing more effective delivery systems, enhancing siRNA design for specificity, and broadening the therapeutic scope to cover malignancies and disorders of the central nervous system. (5). Future developments also involve combining RNA interference (RNAi) with mRNA therapies and CRISPR-Cas gene editing to provide a comprehensive precision medicine strategy. (6).



[Figure number.1][RNA i Pathway]

Historical Context:

In molecular biology, the discovery of RNA interference (RNAi) signaled a paradigm shift. Even though the phenomena of gene silencing in plants was first noticed in the 1990s, nothing was known about it at the time. Napoli et al. discovered unanticipated gene suppression in 1990 while trying to increase petunia pigment production; this phenomena was later dubbed "co-suppression." (7). they were awarded the 2006 Nobel Prize in Physiology or Medicine for this discovery, which laid the groundwork for the RNAi process. Their research demonstrated the promise of RNA interference as a tool for gene regulation and offered the first mechanistic understanding of post-transcriptional gene silencing via dsRNA. Later studies revealed important elements of the RNAi pathway, such as the RNAinduced silencing complex (RISC), Dicer, and Argonaute proteins, which provided insight into the molecular mechanisms of RNAi.8). Therapeutic uses became possible in the early 2000s when it was demonstrated that synthesized small interfering RNAs (siRNAs) could cause RNA interference (RNAi) in mammalian cells without inducing an interferon response.(9).

Scope and Objective:

● Scope

The scope of this review encompasses the molecular mechanisms of RNA interference (RNAi), the development of RNAi-based therapeutics, and the current challenges and future

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

Opportunities in the field. It aims to provide a comprehensive Understanding of how RNAi has evolved from a gene-silencing Phenomenon to a therapeutic strategy with clinical applications.

● **Objective**

1. Summarize the biological underpinnings of RNAi, including its key molecular components and pathways.
2. Examine the progress of RNAi-based therapeutics from preclinical research to approved drugs.
3. Discuss delivery strategies, clinical outcomes, and regulatory milestones.
4. Highlight current limitations such as delivery barriers, off-target effects, and immune responses.
5. Explore future directions, including novel delivery systems, combination therapies, and integration with other genetic tools like CRISPR.[3,4,10]

❖ **Molecular Mechanisms of RNAi:**



RNA type	Mechanism of action	Details
siRNA (small interfering RNA)	Pathway interference	RNA designed to target a specific mRNA for degradation, resulting in gene silencing.
ASO (antisense oligonucleotide)	3D-function	RNA which prevents mRNA physically interacting with proteins involved in splicing or translation.
mRNA (messenger RNA)	Replacement	mRNA can be a replacement for one that is not expressed correctly, or mimic an antigen expressed by a pathogen.
tRNA (transfer RNA)	Replacement	tRNA therapies seek to overcome mutations that result in truncated proteins.
saRNA (self-amplifying RNA)	Replacement	saRNA allows for much greater expression of the protein it seeks to produce.
miRNA (microRNA)	Pathway interference	miRNA therapies inject miRNA that is under-expressed due to genetic mutations.
Aptamers	Pathway interference	Aptamers are molecules that bind to a specific protein, directly moderating protein-protein interactions.

[Figure number.2][Types of RNA based therapeutic]

RNA interference (RNAi) is a conserved biological process in which small RNA molecules regulate gene expression by promoting the

Degradation of target messenger RNA (mRNA) or by inhibiting translation. The process is mediated by two main types of small RNAs: small interfering RNAs (siRNAs) and microRNAs (miRNAs), both of which play critical roles in post-transcriptional gene regulation.

The RNAi pathway begins with the presence of double-stranded RNA (dsRNA) in the cytoplasm. The RNase III enzyme Dicer cleaves long dsRNA or precursor miRNA (pre-miRNA) into small RNA duplexes of approximately 21–25 nucleotides (11). These duplexes are then incorporated into the RNA-induced silencing complex (RISC), a multi-protein complex that plays a central role in gene silencing.

Within RISC, one strand of the RNA duplex (the guide strand) is retained, while the other (the passenger strand) is degraded. The guide strand directs RISC to a complementary target mRNA through base pairing (9). In the case of siRNA, this binding leads to precise cleavage of the mRNA by the Argonaute (AGO) protein, particularly AGO2, which has endonuclease activity (12). This cleavage results in mRNA degradation and subsequent gene silencing .miRNAs, in contrast, are typically only partially complementary to their target mRNAs and often bind to sequences in the 3' untranslated region (3' UTR). This usually results in translational repression and/or mRNA destabilization rather than direct cleavage [2].The specificity and efficiency of RNAi make it a powerful tool for functional genomics and

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, March 2026
Impact Factor: 8.2

therapeutic applications. However, unintended off-target effects and activation of immune responses are challenges that need careful management in therapeutic settings (13).

❖ **Key Components of the RNAi Pathway:**



[Figure number.3 key component]

A coordinated group of molecular elements known as RNA interference (RNAi) recognize, process, and use short RNA molecules to cause gene silencing. These crucial elements are extremely conserved and necessary for the RNAi mechanism to operate correctly.

1. Dicer:

Dicer is an RNase III family endonuclease responsible for cleaving long double-stranded RNA (dsRNA) and precursor microRNAs

(pre-miRNAs) into 21–25 nucleotide small RNA duplexes (11). It plays a central role in generating both siRNAs and miRNAs, serving as the entry point into the RNAi pathway.

2. RNA-Induced Silencing Complex (RISC):

One strand of the short RNA duplex, referred to as the guide strand, is incorporated by the multi protein effector complex known as RISC in order to find complementary mRNA targets. The complementarity between the guide RNA and its target determines whether the RISC promotes translational repression or mRNA cleavage to silence the gene. (8).

3. Argonaute Proteins (AGO):

Among the core components of RISC are Argonaute proteins, particularly AGO2, which is the only Argonaute in humans with endonuclease ("slicer") activity. AGO2 directly mediates the cleavage of target mRNA when perfect base pairing is present (12). AGO proteins also play roles in miRNA-mediated repression and in recruiting other silencing factors.

4. SiRNA and miRNA:

Dicer processes small interfering RNAs (siRNAs), which are usually exogenous or experimentally introduced double-stranded RNAs. However, before loading into RISC, microRNAs (miRNAs) are endogenously generated and processed via a multi-step route including Drosha (in the nucleus) and Dicer (in the cytoplasm). (2).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

5. Drosha-DGCR8 Complex:

For primary microRNA transcripts (pri-miRNAs) to be processed in the nucleus into precursor miRNAs (pre-miRNAs), which are subsequently exported to the cytoplasm for additional processing by Dicer, this complex is necessary. (14).

❖ Development of RNAi based therapeutics:

The development of RNA interference (RNAi) into a therapeutic platform represents a major milestone in Modern medicine, offering a strategy to silence disease-causing genes at the post-transcriptional level. Since its discovery, efforts have focused on translating the RNAi mechanism into safe, specific, and effective treatments for genetic, viral, and cancer-related diseases.

1. Early Challenges and Proof-of-Concept:

Initial studies demonstrated that synthetic small interfering RNAs (siRNAs) could induce gene silencing in mammalian cells without triggering nonspecific immune responses, unlike long double-stranded RNA.

However, early therapeutic attempts faced major hurdles, particularly in delivery, stability, and off-target effects (15).

2. Advancements in Delivery Systems:

A range of formulations and vectors, including as viral vectors, conjugated ligands, and lipid nanoparticles (LNPs), were created in order to get around delivery obstacles. The most effective platform was LNPs, which allowed siRNAs to be delivered systemically and escape endosomally. The creation of N-acetylgalactosamine (GalNAc) conjugates, which selectively target hepatocytes via asiloglycoprotein receptors and enable subcutaneous administration, was a significant breakthrough. (16).

3. First RNAi Therapeutics Approved:

In 2018, Patisiran (Onpattro) became the first FDA-approved RNAi drug for the treatment of hereditary transthyretin-mediated amyloidosis. It uses LNPs to deliver siRNA targeting transthyretin (TTR) mRNA in the liver.

Following this, Givosiran (for acute hepatic porphyria), Lumasiran (for primary hyperoxaluria type 1), and Inclisiran (for hypercholesterolemia) were approved, with in clisiran marking a shift towards chronic disease management using RNAi (17).

4. Expanding Clinical Pipeline:

To overcome delivery challenges, a variety of formulations and vectors were developed, such as conjugated ligands, lipid nanoparticles (LNPs), and viral vectors. LNPs were the most successful platform because they made it possible for siRNAs to be given systemically and escape endosomally. An important development was the development of N-acetylgalactosamine (GalNAc) conjugates, which allow subcutaneous injection and specifically target hepatocytes via asiloglycoprotein receptors.

5. Regulatory and Commercial Milestones:

The FDA and EMA have given RNAi therapies classifications such Orphan Drug, Fast Track, and Breakthrough Therapy, indicating their potential to cure critical and uncommon illnesses.

Development has been further expedited by strategic partnerships and investments. (18).

❖ Clinical applications and approved RNAi therapeutic :

With numerous medications approved for clinical usage and even more in the works, RNA interference (RNAi) has transformed from a potent gene-silencing tool into a recognized therapeutic platform. Although future applications seek to address illnesses in other organs, these therapies primarily target genes expressed in the liver.

1. Approved RNAi Therapeutics:

The majority of RNA interference (RNAi) medications that have been licensed so far target hepatic disorders and employ siRNA, utilizing lipid nanoparticles (LNPs) or GalNAc conjugation for effective delivery. a. Patisiran (Onpattro) Indication: Hereditary

Transthyretin-mediated (hA TTR) amyloidosis with polyneuropathy

Mechanism: LNP-formulated siRNA targeting transthyretin (TTR) mRNA in the liver

Approval: FDA (2018), EMA (2018)

Outcome: Reduced serum TTR levels and improved neurological symptoms

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

b. Givosiran (Givlaari)
Indication: Acute hepatic porphyria (AHP)
Mechanism: GalNAc-conjugated siRNA targeting aminolevulinic acid synthase 1 (ALAS1)
Approval: FDA (2019), EMA (2020)
Outcome: Significant reduction in AHP attacks and toxic metabolite accumulation c. Lumasiran (Oxlumo)
Indication: Primary hyperoxaluria type 1 (PH1)
Mechanism: GalNAc-siRNA targeting glycolate oxidase (GO), reducing oxalate production
Approval: FDA (2020), EMA (2020)
Outcome: Lowered urinary oxalate levels, reducing kidney stone risk (19)
d. Inclisiran (Leqvio)
Indication: Hypercholesterolemia and atherosclerotic cardiovascular disease
Mechanism: GalNAc-siRNA targeting PCSK9 mRNA
Approval: EMA (2020), FDA (2021)
Outcome: Sustained LDL cholesterol reduction with twice-yearly dosing (20)
e. Vutrisiran (Amvuttra)
Indication: h ATTR amyloidosis (alternative to Patisiran)
Mechanism: Subcutaneously delivered GalNAc-siRNA targeting TTR
Approval: FDA (2022), EMA (2022)
Outcome: Similar efficacy to Patisiran with more convenient administration (21)
2. Clinical Pipeline and Emerging Applications:
Many RNAi candidates are undergoing clinical trials for a range of illnesses in addition to authorized medications:
1. Chronic hepatitis B: siRNA
Drugs like JNJ-3989 and VIR-2218 are being tested to lower the antigen load and silence viral transcripts. (22).
2. Liver cancers and fibrosis: RNA interference is being investigated to alter fibrosis pathways
(such as TGF-β, CTGF).
3. Ophthalmology: Drugs based on RNA interference are being investigated for diabetic retinopathy and macular degeneration.
4. Neurological diseases: Trials for conditions including Huntington's and ALS are being fueled by improvements in delivery across the blood-brain barrier.

❖ Challenges in RNAi therapeutics:

Off-Target Effects:
The possibility of off-target effects, which can result in unintentional gene silence and detrimental biological results, is a significant obstacle in the development and practical use of RNA interference (RNAi) therapies. These consequences arise from the unintentional down regulation caused by the RNA-induced silencing complex (RISC) attaching to partly complementary regions in non-target mRNAs. The seed region of the siRNA (nucleotides 2–8 from the 5' end) is largely responsible for off-target effects. It can imitate the process of microRNAs and silence genes with comparable sequences in their 3' untranslated regions.(23). Widespread alterations in gene expression could result from this phenomena, which would raise questions regarding safety, particularly in long-term therapy. Furthermore, excessive siRNA concentrations have the potential to overwhelm the body's RNAi machinery, disrupting normal miRNA processing and producing unexpected outcomes. (24). To improve selectivity and decrease off-target interactions, chemical modifications such 2'-O-methyl or locked nucleic acid (LNA) alterations have been used. (25).
The meticulous design of siRNA sequences, in silico prediction tools, and high-throughput screening assays to find and remove problematic sequences prior to clinical development are some strategies to reduce off-target effects. (26). Enhancing tissue selectivity and reducing systemic exposure are other benefits of ongoing delivery method and targeting mechanism improvement.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, March 2026
Impact Factor: 8.2

Immune Activation:

The possibility of immune system activation, which might result in inflammatory reactions or unfavorable outcomes, is a crucial factor to take into account while developing RNAi therapies clinically. Synthetic siRNAs have the potential to inadvertently activate the innate immune system, especially through pattern recognition receptors such protein kinase R (PKR), RIG-I-like receptors, and Toll-like receptors (TLRs). (27).

Immune cell endosomes contain TLR7 and TLR8, which are especially sensitive to short doublestranded or single-stranded RNAs. When these receptors are activated, proinflammatory cytokines like interferon-alpha and TNF-alpha are produced. (28). both in vitro and in vivo observations of this reaction have been made, particularly when the siRNA contains unmodified or specific sequence patterns. (29).

❖ Advances in delivery technologies :

Nanoparticle Systems:

One of the biggest obstacles in the development of new treatments is the efficient delivery of RNAi molecules to the intended tissues. One of the most promising approaches to get beyond biological barriers, shield RNA from deterioration, and improve cellular uptake is the use of delivery systems based on nanoparticles. Tissue-specific targeting and improved pharmacokinetics are made possible by these systems' ability to encapsulate or complex with siRNA. The most cutting-edge therapeutic delivery systems for RNA interference are lipid nanoparticles (LNPs). They include polyethylene glycol (PEG)-lipid conjugates, phospholipids, cholesterol, and ionizable lipids, which aid in endosomal escape and shield siRNA from serum nucleases.(30). FDA-approved medications like patisiran, which treats hereditary transthyretinmediated amyloidosis, contain LNPs. Apart from LNPs, preclinical research has demonstrated the potential of additional nanoparticle types for RNAi administration, including polymeric nanoparticles, dendrimers, inorganic nanoparticles (such as those based on gold or silica), and exosomes.(31). To improve selectivity and therapeutic results, these platforms can be modified for controlled release, surface modification with ligands (such as GalNAc, antibodies), and codelivery of several therapeutic agents. (32).

Targeted Delivery Approaches:

One of the biggest obstacles to the clinical use of RNAi-based treatments is still ensuring efficient and targeted delivery. Advanced delivery strategies have been developed to improve the stability, cellular internalization, and target specificity of naked siRNAs due to their low cellular absorption and fast bloodstream degradation. One of the most widely used delivery systems is lipid nanoparticles (LNPs), especially for liver-targeted RNA interference treatments.

Following cellular uptake, LNPs wrap siRNA molecules, shield them from nucleases, and enable endosomal escape. An LNP-based delivery system is used by the FDA-approved medication patisiran, which targets transthyretin (TTR) for familial ATTR amyloidosis. Another significant development is the conjugation of GalNAc (N-acetylgalactosamine), which targets the asialoglycoprotein receptor to transport the drug to hepatocytes in a very effective and receptormediated manner. This approach has led to the development of drugs such as givosiran and inclisiran [33].

Targeted delivery is still more complicated outside of the liver. For tissue-specific delivery to cancers and other organs, researchers are investigating aptamer conjugates, antibody-siRNA conjugates (ARCs), and peptide-based vectors. [34]. additionally, exosomes and other extracellular vesicles are being studied as natural, biocompatible carriers capable of transferring RNA molecules across biological barriers [35].

❖ Emerging Applications of RNAi Oncology:

RNA interference (RNAi) is a potent biological process that silences gene expression at the posttranscriptional level. Its therapeutic potential in oncology is significant due to its specificity in targeting oncogenes and cancer-related pathways.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

1. Targeting Oncogenes:
RNAi can specifically knock down the expression of mutated or overexpressed oncogenes such as KRAS, BCL2, and MYC. This selective silencing allows researchers to study gene function and develop gene-specific cancer therapies.
2. Overcoming Drug Resistance:
RNAi has shown promise in sensitizing tumors to chemotherapeutic agents. For example, silencing genes involved in drug resistance, such as MDR1 or ABCB1, can restore chemotherapy effectiveness.
3. Immunotherapy Enhancement:
RNAi is being explored to modulate immune checkpoint pathways. By silencing PD-L1 or other immune-suppressive genes in tumor cells, RNAi can enhance T-cell responses and improve the efficacy of immunotherapies.
4. Nanoparticle-Mediated Delivery:
Recent advances in delivery systems, particularly lipid nanoparticles (LNPs), have enhanced the clinical viability of RNAi therapies. LNP-based RNAi formulations are now being used in clinical trials for targeting solid tumors.
5. Clinical Trials and FDA Approval:
The success of patisiran (for amyloidosis) has paved the way for RNAi therapeutics in oncology. Several candidates, like siRNA-based agents targeting VEGF or EphA2, are under investigation in clinical trials for cancers such as ovarian and liver cancer.[36]
Infectious Diseases:
RNA interference (RNAi) has emerged as a powerful tool to combat infectious diseases by silencing viral and bacterial genes essential for replication, survival, or pathogenesis. It holds promise for both therapeutic and diagnostic applications.
1. Antiviral Therapy:
RNAi has shown strong efficacy against viruses such as HIV, hepatitis B and C, influenza, and more recently, SARS-CoV-2. By targeting viral RNA or host factors crucial for viral replication, RNAi can inhibit infection at the molecular level.
2. HIV and Hepatitis:
SiRNAs have been created to target host receptors like CCR5 as well as important HIV genes including gag, pol, and tat. In clinical trials, siRNA therapies like JNJ-3989 have demonstrated strong HBV DNA decrease in hepatitis B.
3. SARS-CoV-2 (COVID-19):
Several preclinical studies demonstrated that siRNAs targeting the viral spike or RNA-dependent RNA polymerase (RdRp) genes could significantly reduce viral replication. Delivery systems though less explored, RNAi has potential in targeting antibiotic-resistant bacterial genes or virulence factors, especially in intracellular pathogens like Mycobacterium tuberculosis.
4. Diagnostics and Functional Genomics:
RNAi is also used to identify host-pathogen interactions and essential genes in pathogens, enabling the discovery of novel drug targets and vaccine candidate.[37]
Genetic Disorders:
RNA interference (RNAi) offers a highly specific approach to down regulate the expression of disease-causing genes, particularly in monogenic disorders. The clinical utility of RNAi is expanding, with several therapies in clinical trials or approved for genetic diseases.
1. Transthyretin Amyloidosis (hATTR):
The first FDA-approved RNAi therapeutic, patisiran, treats hereditary transthyretin-mediated amyloidosis by silencing the TTR gene, reducing toxic protein accumulation and improving neurological function. 2. Hypercholesterolemia:
Inclisiran, asiRNA drug, targets PCSK9, a gene that regulates cholesterol metabolism. By silencing PCSK9, it lowers LDL cholesterol levels in patients with familial hypercholesterolemia and atherosclerotic cardiovascular disease.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

3. Alpha-1 Antitrypsin Deficiency:
Through gene replacement techniques, RNA interference (RNAi) is being investigated to decrease the synthesis of the mutant SERPINA1 protein that damages the liver while permitting the production of functional proteins.
4. Huntington's Disease:
In order to selectively target mutant HTT mRNA and lower the expression of the toxic huntingtin protein that causes neuronal degeneration, siRNAs and shRNAs are being developed.
5. Other Genetic Disorders:
The use of RNA interference (RNAi) in disorders such as dominantly inherited retinal dystrophies, thalassemias (by inhibiting fetal hemoglobin repressors), and spinocerebellar ataxias is still being studied.[3,38]

❖ **Future Directions: Next-Generation RNAi Molecules:**

The future of RNAi-based therapeutics is closely tied to the development of next-generation RNAi molecules that offer improved potency, specificity, stability, and delivery profiles. These novel constructs are designed to overcome key limitations of first-generation small interfering RNAs (siRNAs), such as degradation by nucleases, off-target effects, and inefficient cellular uptake.
Chemically modified siRNAs are at the forefront of this innovation. Modifications such as 2'-Omethyl (2'-OMe), 2'-fluoro (2'-F), and phosphorothioate linkages enhance nuclease resistance and reduce immunogenicity while maintaining silencing efficiency [39]. Another promising advancement is the use of Dicer-substrate siRNAs (DsiRNAs), which are longer than conventional siRNAs and show enhanced potency and duration of action due to more efficient processing by Dicer [40].
Self-delivering RNAi molecules (sd-RNAs) represent a significant step forward by combining siRNA and delivery moieties into a single molecule, eliminating the need for complex delivery systems [41]. Additionally, small hairpin RNAs (shRNAs) and artificial microRNAs (am iRNAs) expressed from DNA vectors are being developed for long-term gene silencing, which may be particularly beneficial in treating chronic diseases [42].
Efforts are also underway to create tissue-specific RNAi therapeutics using ligand-conjugated siRNAs. For instance, N-acetylgalactosamine (GalNAc) conjugates have shown great success in targeting hepatocytes and have been integral to the approval of multiple RNAi-based drugs [43]. As the field develops, creating programmable RNAi constructs or combining CRISPR technologies with RNAi may increase treatment options and improve gene regulation techniques. With the help of continuing clinical research and the development of these next-generation agents, RNA interference (RNAi) is positioned as a key modality in the future of precision medicine.

Advancements in Delivery:

One of the biggest obstacles to the clinical use of RNAi therapies is still effective delivery. The stability, specificity, and bioavailability of RNAi compounds have been greatly improved by recent developments in delivery technology, which has made it easier for them to go from bench to bedside. The creation of lipid nanoparticle (LNP) formulations, which encapsulate siRNAs and shield them from enzymatic breakdown while encouraging cellular absorption via endocytosis, has been one of the most significant discoveries. FDA-approved RNAi medications like patisiran, the first siRNA therapy authorized for hereditary transthyretin-mediated amyloidosis, have been made possible in large part by NPs. Improved tissue targeting and decreased toxicity have resulted from ongoing LNP composition refining, which includes ionizable lipids and PEGylation. [44].
Another significant advancement is the use of ligand-targeted conjugates, particularly Nacetylgalactosamine (GalNAc) conjugation, which enables efficient and receptor-mediated delivery of siRNAs specifically to hepatocytes through asialoglycoprotein receptors. GalNAcsiRNA conjugates allow for subcutaneous administration with improved patient compliance and have been key to the success of second-generation RNAi drugs such as givosiran and inclisiran.
Alternative delivery systems such as exosomes, aptamer-siRNA chimeras, and polymeric nanoparticles are under active investigation. Exosome-based delivery leverages the natural biocompatibility and cell-targeting capabilities of extracellular vesicles, offering a promising platform for non-immunogenic RNAi delivery [45]. Additionally,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

biodegradable polymer carriers like PLGA (poly lactic-co-glycolic acid)) and cell-penetrating peptides (CPPs) are being investigated to improve endosomal escape and extend circulation time. [46].

By increasing the number of disorders that can be treated, decreasing the frequency of dosage, and enhancing the therapeutic index, these delivery improvements taken together are changing the landscape of RNAi therapy.

Global Impact:

Since they provide promising treatments for diseases that were previously incurable and address important unmet medical needs, RNA interference (RNAi) medicines have had a significant impact on the medical landscape worldwide. Since traditional treatments for cancer, infectious diseases, and uncommon genetic abnormalities have frequently been insufficient or unsuccessful, the development of RNA interference (RNAi) technology has proven very beneficial in these areas. RNA interference (RNAi) has opened up a new treatment option for rare genetic illnesses, including acute hepatic porphyria and hereditary transthyretin amyloidosis (hATTR). By inhibiting the transthyretin gene and lowering the accumulation of harmful proteins in the body, Patisiran, the first FDA-approved RNA interference medication, is a historic accomplishment that can change the lives of people with hATTR. [47]. Additional RNAi-based treatments that target a variety of genetic alterations have been made possible by this breakthrough. As an illustration of RNAi's capacity to treat inherited metabolic illnesses worldwide, givosiran and lumasiran are RNAi therapies that target the liver enzymes implicated in porphyria and primary hyperoxaluria, respectively.[48].

In the fight against infectious diseases, RNAi-based approaches are being developed for both prophylactic and therapeutic purposes. During the COVID-19 pandemic, RNAi was explored as a potential strategy to inhibit viral replication, with promising preclinical data indicating that siRNAs could effectively target key viral genes [49]. Furthermore, because RNA interference (RNAi) may target the genetic material of pathogens, it has sparked interest in treating diseases like hepatitis, HIV, and the Zika virus, which continue to be major global health concerns. The potential of RNA interference to combat cancer is another example of its worldwide influence.

RNAi-based medicines are being researched to suppress tumor growth and improve the effectiveness of current cancer treatments by silencing oncogenes. Targeting particular genes implicated in the development of cancer holds hope for customized medicine by lowering the adverse effects usually connected to traditional cancer treatments. [50].

The success of RNAi therapies has sparked interest in research around the world, especially in nations like China, the US, and the EU that have thriving biotechnology industries. In addition to treating rare and orphan diseases, the broad use of RNAi technology will have significant public health ramifications by offering a novel class of therapies that can be tailored to treat a range of illnesses in a variety of demographics.

II. CONCLUSION

RNAi-based therapeutics have transitioned from a groundbreaking discovery in gene regulation to a clinically validated modality with substantial global impact. The approval of drugs such as patisiran, givosiran, and inclisiran has demonstrated the clinical feasibility and therapeutic potential of RNAi in treating genetic and metabolic disorders, particularly those involving the liver. Innovations in chemical modification, delivery platforms, and tissue-specific targeting have significantly improved the stability, specificity, and safety of RNAi molecules, addressing many of the challenges that initially limited their clinical application [51].

Looking forward, the development of next-generation RNAi constructs—including Dicersubstrate siRNAs, self-delivering RNAi molecules, and ligand-conjugated systems—holds promise for expanding the therapeutic reach of RNAi into areas such as oncology, infectious disease, and chronic conditions. Additionally, emerging delivery technologies such as GalNAc conjugation and lipid nanoparticles have laid the foundation for more efficient and patientfriendly drug formulations.

While hurdles such as off-target effects, immune responses, and delivery to non-hepatic tissues persist, continued advancements in molecular design and delivery science are expected to overcome these limitations. RNAi therapeutics are poised to become a cornerstone of precision medicine, offering tailored, gene-specific interventions with the potential to transform the treatment landscape for numerous diseases worldwide.[52]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, March 2026
Impact Factor: 8.2

REFERENCES

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference byDouble-stranded RNA in Caenorhabditis elegans. Nature.1998; 391(6669):806–811.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–297.
3. Adams D, Gonzalez-Duarte A,O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for Hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379(1):11–21.
4. Balwani M, Sardh E, Ventura P, et al. Givosiran for the treatment of acute hepatic porphyria: a phase 1–2 and randomized, controlled, phase 3 trial. N Engl J Med. 2020; 382(24):2289–2301.
5. Setten RL, Rossi JJ, Han SP. TheCurrent state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019; 18(6):421–446.
6. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213):1258096.
7. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 1990; 2(4):279–289.
8. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science. 2001; 293(5532):1146–1150.
9. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836):494–498.
10. Guo P, Coban O, Snead NM, Trebley J, Hoeprich S, Guo S, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev. 2010; 62(6):650–666.
11. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001; 409(6818):363–366.
12. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004; 305(5689):1437–1441.
13. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003; 21(6):635–637.
14. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415–419.
15. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129–138.
16. Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent Nacetylgalactosamine-conjugated siRNA for targeted delivery to hepatocytes. J Am Chem Soc. 2014; 136(49):16958–16961.
17. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017; 376(15):1430–1440.
18. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-inhumans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013; 3(4):406–417.
19. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021; 384(13):1216–1226.
20. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020; 382(16):1507–1519. 21. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379(1):22–31.
22. Yuen MF, Gane E, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, et al. Antiviral activity, safety, and pharmacokinetics of VIR-2218, an RNAi therapeutic targeting hepatitis B virus, in healthy volunteers and patients with chronic HBV infection. J Hepatol. 2021; 75(1):64–77.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, March 2026
Impact Factor: 8.2

23. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods. 2006; 3(3):199 – 204.
24. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006; 441(7092):537–41.
25. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009; 37(9):2867–81.
26. Birmingham A, Anderson EM, Reynolds A, Kesari S, Fedorov Y, Baskerville S, et al. Statistical analysis of off-target effects in RNA interference screens. Nat Methods. 2007; 4(9):849–51.
27. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005; 11(3):263–70.
28. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Speciesspecific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303(5663):1526–9.
29. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 2005; 348(5):1079–90.
30. Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019; 14(12):1084–7.
31. Kanasty R, Dorkin JR, Vegas A, Anderson DG. Delivery materials for siRNA therapeutics. Nat Mater. 2013; 12(11):967–77.
32. Wang Y, Miao L, Satterlee A, Huang L. Delivery of RNAi therapeutics to the tumor microenvironment with nanoparticles. Nanomedicine. 2015; 10(11):1939–56.
33. Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, et al. Antisense oligonucleotides: An emerging area in drug discovery and development. J Clin Med. 2020; 9(7):2004.
34. Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides. 2011; 21(1):1–10.
35. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27(9):839–49.
36. Kim DH, Rossi JJ. RNAi mechanisms and applications. Biotechniques. 2008; 44(5):613– 616.
37. Pushparaj PN, Aarthi JJ, Manikandan J, Kumar SD. RNAi and RNAa—the Yin and Yang of RNAome. Biotechnol Adv. 2008; 26(6):613–621.
38. Davidson BL, McCray PB Jr. Current prospects for RNA interference–based therapies. Nat Rev Genet. 2011; 12(5):329–340.
39. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006; 13(3):494-505.
40. Robbins M, Judge a, MacLachlan I. siRNA and innate immunity. Oligonucleotides. 2009; 19(2):89-102.
41. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007; 25(10):1149-1157.
42. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008; 105(15):5868-5873.
43. Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014; 136(49):16958–16961.
44. Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, van der Meel R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021; 16(6):630–643.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, March 2026 Impact Factor: 8.2

45. Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017; 25(1):71–78.
46. El Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347–357.
47. Anderson KE, Block J, Dalli C, et al. Givosiran, an RNA interference therapeutic, in patients with acute hepatic porphyria. N Engl J Med. 2020; 382(24):2297-2306.
48. Amy D, Cassander B, Saylor J, et al. Lumasiran, an investigational RNA interference therapeutic, for primary hyperoxaluria type 1. N Engl J Med. 2020; 382(19):1828–1839.
49. Guzman S, Liao X, Chen S, et al. Preclinical efficacy of siRNAs targeting SARS-CoV-2: development of a potential antiviral therapeutic. Nat Common. 2020; 11(1):5784.
50. Mookhtiar AK, Wallace TL, Alexander RS, et al. RNA interference therapeutics: the future of cancer treatment. Cancer Gene Ther. 2019; 26(5):155-163.
51. Anderson KE, Block J, Dalli C, et al. Givosiran, an RNA interference therapeutic, in patients with acute hepatic porphyria. N Engl J Med. 2020; 382(24):2297-2306.
52. Robbins M, Judge a, MacLachlan I. siRNA and innate immunity. Oligonucleotides. 2009; 19(2):89–102.